"Pre-IPO" Biotech Startup Kills Advanced Stage Breast Cancers; Accepts Global Crowdfunding Investors

SAN FRANCISCO: SAN FRANCISCO, Oct. 14, 2021 /PRNewswire/ -- In recognition of Breast Cancer Awareness Month, DeoBioSciences, Inc. ("DBS"), a minority/female founded, preclinical stage, biotech company, is highlighting its impressive research results against several types of treatment-resistant breast cancer. DeoBioSciences' drug candidate, DBX-31, can selectively target and kill a wide...

Click to view original post